Objective To identify the risk factors for imipenem resistance development and transmission of clinical Pseudomonas aeruginosa isolates. Methods Thirty-seven imipenem unsusceptible Pseudomonas aeruginosa isolates collected from patients in absence of carbapenem treatment were characterized by antimicrobial susceptibility test, pulsed field gel electrophoresis (PFGE) and carbapenem resistant mechanism analysis. Results Before the collection of imipenem unsusceptible Pseudomonas aeruginosa isolates, the average time of patients treated with more than one antimicrobial (20.0 ± 9.5 days, n = 16) was significantly longer than those treated with only one antimicrobial (12.6 ± 4.4 days, n = 21; t-test, Welch, t = -2.9004, P < 0.01). And 32 isolates showed resistance to more than 3 classes of antimicrobials. Six PFGE clusters were identified and 26 isolates were grouped into one dominant cluster (C2). An ISpa1328 sequence insertion in oprD was detected in 33 isolates and the function of efflux was observed in all 37 isolates in the presence of a wide spectrum efflux inhibitor. Conclusions Our data demonstrated that exposure to non-carbapenem drug classes, especially fluoroquinolones and β-lactams, may be important risk factors for the spread of carbapenem resistant Pseudomonas aeruginosa.
P
seudomonas aeruginosa (P. aeruginosa) is one of the leading nosocomial pathogens associated with a high morbidity and mortality rate worldwide. 1 As it has remarkable ability of acquiring resistance mechanisms to multiple groups of antimicrobial agents, the increasing prevalence of nosocomial infections produced by multidrugresistant P. aeruginosa isolates, including isolates with resistance to broad-spectrum-lactams, aminoglycosides and fluoroquinolones, has severely compromised the selection of appropriate treatment.
2 Carbapenems are currently one of the empirical options to treat multidrug-resistant P. aeruginosa infections.
3 However, carbapenem resistance is also sharply increasing worldwide and jeopardizes the few therapeutic options in multidrug-resistant P. aeruginosa infection treatment.
as metalloenzymes. 1 The emergence and transmission of carbapenem resistant isolates have been related to the use of carbapenems. 5 Recently, the emergence of carbapenem resistance in P. aeruginosa isolates from a patient in the absence of carbapenem therapy has attracted attention to the factors contributing to the emergence and spread of carbapenem resistant P. aeruginosa. 6 The effect of using other antimicrobials in the emergence and transmission of carbapenem resistant isolates was not clear. Clinical studies are needed to identify risk factors for imipenem resistance development and the characteristics of P. aeruginosa isolates that have emerged without carbapenem treatment.
In this study, 37 imipenem resistant P. aeruginosa isolates recovered from individual inpatients in absence of carbapenem treatment were analyzed. Risk factors of imipenem resistance emergence and imipenem resistance mechanisms in these isolates were characterized.
MATeRIAls And MeThOds

Bacterial strains
In total, 37 non-duplicate imipenem unsusceptible P. DOI: 10.1515 DOI: 10. /ii-2017 aeruginosa isolates [imipenem minimum inhibitory concentration (MIC) = 8 mg/L (n = 5) or 16 mg/L (n = 32)] recovered from the airway secretion sample of individual patient in 3201 Hospital (Hanzhong, China) were included in this study. And all these imipenem resistant isolates were recovered for the first time from these patients after treatment. The 3201 Hospital is a 1000-bed, university-affiliated medical center that is located in southwest of China and is one of the sentinel hospitals in the network of National Center for Surveillance of Antimicrobial Resistance. These isolates were collected from neurosurgery (18 isolates), respiratory medicine (10 isolates), hepatobiliary surgery (4 isolates) and other sections (5 isolates) from July 2007 to March 2008 (Figure 1 ). All P. aeruginosa isolates were identified by the API 32GN system (BioMerieux, France). P. aeruginosa ATCC27853, IMP-1 or VIM-2 producing P. aeruginosa isolates and P. aeruginosa PAO1 were taken as control strains in susceptibility testing and β-lactamase assays.
Antimicrobial susceptibility testing
The minimal inhibitory concentrations (MICs) to 11 antimicrobials were measured via broth microdilution method for all 37 P. aeruginosa isolates, including amikacin, colistin, cefepime, cefotaxime, ceftazidime, ciprofloxacin, imipenem, meropenem, piperacillintazobactam, trimethoprim-sulfamethoxazole and tetracycline. All susceptibility results were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) interpretive standards.
7 All 37 isolates were screened for metallo-β-lactamase production by E-test (imipenem/EDTA) (AB BIODISK, Sweden) method according to the manufacture's instructions.
Pulsed-field gel electrophoresis (PFGe)
All 37 imipenem unsusceptible P. aeruginosa stenotrophomonas maltophiliaisolates were analyzed by PFGE to determine DNA fingerprinting profiles resulting from digestion by restriction enzymes Spe I according to the reference method with minor modifications.
8 Briefly, bacteria were grown and suspended in cell suspension buffer (100 mmol/L Tris HCl, 100 mmol/L EDTA; pH 8.0) and adjusted to an optical density of 0.52 to 0.56 MCF. The cell suspension (200 µl) was mixed with 10 µl proteinase K (20 mg/ml) and an equal volume of melted 1% agarose. After solidification, the agarose plugs were treated with proteinase K for 2 hours in a water bath at 54℃ with agitation at 180 rpm. The plugs were washed and treated with 50 U Spe I (New England Biolab, Beijing LTD) for two hours in a water bath at 37℃. The resulting DNA fragments were resolved by electrophoresis in a 1% agarose gel using a Chef Mapper (Bio-Rad, Beijing, China) with pulse times of 2.16 s to 63.8 s.
The gel was stained with ethidium bromide, and DNA bands were visualized with a UV transilluminator. The interpretation of the PFGE patterns was performed with BioNumerics software (Applied Maths, Belgium) by the Dice Similarity coefficient. The tree indicating relative genetic similarity was constructed on the basis of the Unweighted Pair Group Method of Averages (UPGMA), with position tolerance of 1%. Clusters were defined as DNA patterns sharing ≥ 85% similarity (C1, C2, C3, ···).
PCR amplification and DNA sequence analysis
Metallo-β-lactamase encoding genes, including blaIMP, blaVIM, blaGIM, blaSPM and blaSIM were amplified by PCR as previously described. [9] [10] [11] [12] [13] Other β-lactamase encoding genes, including blaTEM, blaOXA and blaSHV were also screened.
14,15 PCR amplification of oprD sequence was performed as previously reported. 16 The expression of ampC was determined by real-time reverse transcriptase PCR (RT-PCR) as previously described and compared to the control strain PAO1. More than 10-fold ampC expression was considered as over-expression.
17 All purified PCR products were sequenced and the sequences obtained were analyzed by Sequencher 4.6 software (Gene Codes Corporation, USA).
Efflux analysis
To investigate the contribution of efflux in imipenem resistance, the MIC of imipenem was determined by broth microdilution method in the presence or absence of the wide-spectrum efflux inhibitor phenyl-arginine-β-naphthylamide (PAβN, 50 mg/L, Sigma-Aldrich).
statistical methods
The antimicrobial treatment time of the patients treated with one or more antimicrobials was compared by t-test with Epi Info 6 software (www.cdc.gov/epiinfo/).
ResUlTs epidemiological data of P. aeruginosa isolates
For each patient, the average recovery time of the first imipenem unsusceptible isolate was 15.8 ± 7.9 days (n = 37) after the patients were treated with antimicrobials. Twenty-one P. aeruginosa isolates were isolated from patients treated with one antimicrobial, with the average course of therapy as 12.6 ± 4.4 days; 16 isolates were isolated from patients treated with two to four antimicrobials, with the average course of therapy as 20.0 ± 9.5 days, which was significantly longer than those treated with one antimicrobial (t-test, Welch, t = -2.9004, P < 0.01). Among the 37 patients, 26 were treated with β-lactams, including ceftizoxime (n = 10), ceftazidime (n = 8), cefotaxime (n = 4), azlocillin (n = 2), cefoperazone (n = 2), cefepime (n = 1) and piperacillin-tazobactam (n = 1). Twentytwo patients were treated with fluoroquinolones, including levofloxacin (n = 14), gatifloxacin (n = 6) and ciprofloxacin (n = 2). The amout of patients treated with β-lactams only and fluoroqinolones only were 12 and 10, respectively, and 11 patients received both fluoroquinolones and β-lactams for treatment. Total of 8 patients were treated with gentamicin (n = 7) or azithromycin (n = 1).
Resistance profiles of these isolates All 37 P. aeruginosa isolates were susceptible to colistin and cefepime based on the CLSI breakpoints, but 32 isolates showed MIC to cefepime as either 8 mg/L (n =16) or 16 mg/L (n = 16) and 33 isolates showed MIC to meropenem either as 4 mg/L (n = 25) or 8 mg/L (n = 8). Resistance to tetracycline was the most common (100%, 37/37) followed by trimethoprimsulfamethoxazole (86.5%, 32/37) and amikacin (85.1%, 32/37). The prevalence of resistance to cefotaxime and ceftazidime were 16/37 and 3/37. Among the 37 isolates, 13 isolates were resistant to ciprofloxacin, and 23 isolates showed MIC to ciprofloxacin either as 1 mg/L (n = 5) or 2 mg/L (n = 18). Total of 11 unique antimicrobial resistant profiles were identified among these 37 isolates and 32 isolates showed resistance to more than 3 classes of antimicrobials (Figure 1 ).
PFGe and antimicrobial resistance mechanisms analysis
In total, six PFGE clusters were identified among 37 P. aeruginosa imipenem unsusceptible isolates and 26 isolates were grouped into one dominant cluster (C2). All isolates were phenotypically negative for metallo-β-lactamase by E-test method, but blaIMP-9 was detected in isolate 15 by PCR and further confirmed by sequence analysis. An ISpa1328 sequence insertion at position 117 nucleotides downstream of the oprD translational start codon was found in 33 isolates. The sequences flanking the IS elements represent the direct repeat sequence of the oprD (8 bp). blaOXA-10 was detected In this study, 6 PFGE clusters were identified among 37 imipenem unsusceptible isolates which demonstrated that different P. aeruginosa clones unsusceptible to imipenem might exist in this hospital. But an identical ISPa1328 sequence was detected in oprD at the same insertion position among the 32 isolates. Loss of OprD porin has been widely reported as a typical mechanism for imipenem resistance and reduced susceptibility to meropenem in P. aeruginosa. 21, 22 ISPa1328 was first detected in 4 clinical isolates from Texas of the United States and also reported in a recent study of Chinese isolates. 23, 16 Why this insertion sequence was so widely distributed among P. aeruginosa isolates of different genotypes was still not clear. Extensive studies should be conducted to characterize the transposition mechanism of this transposon among clinical isolates.
In previous studies, metallo-beta-lactamases have been widely reported among imipenem resistant P. aeruginosa isolates.
24 But in this study, all 37 isolates were phenotypically negative for metallobeta-lactamases and only one isolate was positive by PCR, the metallo-beta-lactamases gene was not well expressed even in this isolate as shown by the E-test. Besides OprD porin inactivation, inhibition of efflux by PAβN in these imipenem unsusceptible isolates could also increase the susceptibility to carbapenems. These data indicated efflux was another carbapenem resistance mechanism widely distributed in these isolates, such as mexEF-oprN overexpression as previously reported. 25 We reported the emergence and spread of carbapenem resistance among patients never treated with carbapenem were related to the use of fluoroquinolones or β-lactams, especially the treatment of one antimicrobial. Prudent antimicrobial selection policies combined with good infection control practices should be adopted to stop the development and spread of carbapenem resistance, and to ensure that these important agents could maintain their efficiency in the therapy of P. aeruginosa infections.
in 36 isolates, blaTEM-1 was detected in 33 isolates ( Figure 1 ). All 37 isolates were negative for blaGIM, blaSHV, blaSPM, blaSIM and blaVIM by PCR. In the presence of PAβN, the susceptibility to imipenem was increased 2-(5 isolates), 4-(19 isolates) and 8-fold (13 isolates), respectively; susceptibility to meropenem was increased 2-(3 isolates), 4-(2 isolates), 8-(30 isolates) and 16-fold (2 isolates), respectively. AmpC overexpression was identified in 2 isolates (isolates 40 and 46).
dIsCUssIOn
The identification of risk factors that contribute to the emergence and transmission of carbapenem-resistant P. aeruginosa isolates is critical for nosocomial infection prevention and clinical treatment. Previous studies have recognized different risk factors that are related to the emergence and transmission of carbapenem resistant P. aeruginosa isolates, including prior carbapenem exposure, 18,19 ICU stay, 4 patientto-patient transmission, 20 etc. Recently, a case study showed chronic exposure to unrelated drug classes might be an important determinant for the emergence of carbapenem resistance in P. aeruginosa. 6 Our data showed that the use of non-carbapenem antimicrobials, especially fluoroquinolones and cephalosporins could select P. aeruginosa unsusceptible to carbapenem. But more than 2 classes of antimicrobial application could significantly delay the colonization of isolates unsusceptible to imipenem. These data suggested the emergence of carbapenem resistance should not only be considered among patients receiving carbapenem treatment but also among patients absent of carbapenem treatment.
In this study, 32 out of 37 P. aeruginosa isolates unsusceptible to imipenem showed resistance to more than 3 classes of antimcrobials which further emphasized the remarkable ability of these bacteria to acquire resistance mechanisms of multiple groups of antimicrobial agents.
1 The multi-drug resistance phenotypes of these isolates further verified that other antimicrobials application were risk factors for the colonization of carbapenem resistant isolates. Most isolates showed resistance or intermediate susceptibility to fluoroquinolones and the third generation cephalosporins which were the preferred antimicrobials to P. aeruginosa infections in local hospitals. Since noncarbapenem antimicrobials could also select imipenem unsusceptible isolates and accelerate their transmission in local hospitals, targeted approaches should be developed to stop or slow down the transmission of carbapenem resistance in absence of carbapenem treatment and to protect carbapenem clinical efficiency.
